Infant CD4 T-Cell Response to SARS-CoV-2 mRNA Vaccination Is Restricted in Cytokine Production and Modified by Vaccine Manufacturer - Scorecard - MDSpire
Advertisement
Infant CD4 T-Cell Response to SARS-CoV-2 mRNA Vaccination Is Restricted in Cytokine Production and Modified by Vaccine Manufacturer
Clinical Scorecard: Limited Cytokine Production in Infant CD4 T-Cell Responses Following SARS-CoV-2 mRNA Vaccination Influenced by Vaccine Manufacturer
At a Glance
Category
Detail
Condition
SARS-CoV-2 infection and COVID-19 disease
Key Mechanisms
CD4 T-cell cytokine production (IL-2, TNF-α, IFN-γ) following mRNA vaccination
Target Population
Infants under 12 months receiving SARS-CoV-2 mRNA vaccines
Care Setting
Pediatric vaccination and immunization clinics
Key Highlights
Infants show significant increases in IL-2 and TNF-α producing CD4 T-cells post SARS-CoV-2 mRNA vaccination but limited IFN-γ induction compared to adults.
Th2 and Th17 CD4 T-cell responses are limited in both infants and adults after vaccination.
Infant CD4 T-cell responses are greater with mRNA-1273 vaccine compared to BNT162b, despite similar spike-specific IgG titers.
Guideline-Based Recommendations
Diagnosis
Assess CD4 T-cell cytokine responses (IL-2, TNF-α, IFN-γ) post SARS-CoV-2 mRNA vaccination to evaluate cellular immunity in infants.
Management
Administer SARS-CoV-2 mRNA vaccines (BNT162b or mRNA-1273) according to pediatric dosing schedules for infants >6 months.
Consider vaccine manufacturer differences as mRNA-1273 may induce stronger CD4 T-cell responses in infants.
Monitoring & Follow-up
Monitor spike-specific IgG titers and CD4 T-cell cytokine production post vaccination to assess immune response quality.
Observe for potential differences in immune response magnitude between vaccine types in infants.
Risks
Lower efficacy against symptomatic COVID-19 in infants compared to adults despite robust antibody titers.
Potential limited induction of IFN-γ producing CD4 T-cells in infants may affect cellular immunity.
Patient & Prescribing Data
Infants under 12 months receiving primary SARS-CoV-2 mRNA vaccination series
Infants vaccinated with mRNA-1273 show greater CD4 T-cell cytokine responses than those vaccinated with BNT162b, although antibody levels are comparable.
Clinical Best Practices
Use age-appropriate dosing and schedules for SARS-CoV-2 mRNA vaccines in infants.
Evaluate both humoral (IgG titers) and cellular (CD4 T-cell cytokine) immune responses post vaccination.
Consider vaccine choice impact on cellular immunity when vaccinating infants.
Collect and analyze peripheral blood mononuclear cells for detailed immune profiling when feasible.
by M Quinn Peters, Amber L Young, Jennifer E Stolarczuk, Madeline Glad, Erik Layton, Jennifer K Logue, Nana K Minkah, Helen Y Chu, Janet A Englund, D Noah Sather, Chetan Seshadri, Alisa Kachikis, Whitney E Harrington
